Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 Next >
Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause
From Bayer
Via Business Wire
Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting
From Bayer
Via Business Wire
Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
From Bayer
Via Business Wire
Study Design and Baseline Characteristics of Prespecified, Exploratory Pooled Analysis to Investigate Effect of Finerenone on Cardio-Kidney Outcomes in Patients with CKD and Type 2 Diabetes and/or Heart Failure Shared at Heart Failure 2024 Congress
From Bayer
Via Business Wire
One A Day® Partners with Julian Edelman to Share #WellnessConfessionals
From Bayer
Via Business Wire
Bayer to Present Investigational Data from Comprehensive KERENDIA® (finerenone) Clinical Trial Program at Heart Failure 2024 Congress
From Bayer
Via Business Wire
WomenHeart and Bayer Join Forces to Enhance Heart Health Awareness and Education Among Women Across the U.S.
From Bayer
Via Business Wire
Midol® Addresses Period Education and Normalization of Menstrual Discomfort with PeriodTalk Initiative in Partnership with Nonprofit PERIOD.
From Bayer
Via Business Wire
Bayer to unveil late-breaking data from Phase III OASIS 1 and 2 for elinzanetant in the treatment of vasomotor symptoms associated with menopause
From Bayer
Via Business Wire
Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues
From Bayer
Via Business Wire
Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography
From Bayer
Via Business Wire
Bayer and Google Cloud to accelerate development of AI-powered healthcare applications for radiologists
From Bayer
Via Business Wire
Bayer’s Consumer Health Division Announces Changes to North America Leadership Team
From Bayer
Via Business Wire
Bayer Appoints Sue Ann Pentecost as Vice President, Head of U.S. Pharmaceutical Communications
From Bayer
Via Business Wire
Aleve® Speaks The Painful Truth, Encouraging Consumers to Explore Their Pain Management Options
From Bayer
Via Business Wire
Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines
From Bayer
Via Business Wire
Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth
From Bayer
Via Business Wire
Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant
From Bayer
Via Business Wire
Bayer Wins Third Consecutive Trial Victory
From Bayer
Via Business Wire
Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations
From Bayer
Via Business Wire
Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis
From Bayer
Via Business Wire
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure
From Bayer
Via Business Wire
Bayer Unveils Groundbreaking Solar Energy Projects at Sites in New Jersey and California
From Bayer
Via Business Wire
Bayer appoints Nelson Ambrogio as new Head of Radiology Business at Pharmaceuticals Division
From Bayer
Via Business Wire
MiraLAX® Exposes The Gut Gap™, Proving Women are More Stressed and More Constipated than Men
From Bayer
Via Business Wire
Bayer Reveals Latest Prostate Cancer Data at 2024 ASCO GU Cancers Symposium
From Bayer
Via Business Wire
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause
From Bayer
Via Business Wire
Bayer’s elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies
From Bayer
Via Business Wire
Bayer Statement on Win in Jones Roundup™ Trial
From Bayer
Via Business Wire
Bayer and Salus Optima Partner on AI-Enabled Healthy Aging Journey
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.